Search by Drug Name or NDC
NDC 42192-0626-16 Pyridostigmine Bromide 60 mg/5mL Details
Pyridostigmine Bromide 60 mg/5mL
Pyridostigmine Bromide is a ORAL SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Acella Pharmaceuticals, LLC. The primary component is PYRIDOSTIGMINE BROMIDE.
MedlinePlus Drug Summary
Pyridostigmine is used to decrease muscle weakness resulting from myasthenia gravis.
Related Packages: 42192-0626-16Last Updated: 04/07/2024
MedLinePlus Full Drug Details: Pyridostigmine
Product Information
| NDC | 42192-0626 |
|---|---|
| Product ID | 42192-626_074b1af6-991d-d376-e063-6394a90a26c7 |
| Associated GPIs | |
| GCN Sequence Number | 004763 |
| GCN Sequence Number Description | pyridostigmine bromide SOLUTION 60 MG/5 ML ORAL |
| HIC3 | J1B |
| HIC3 Description | CHOLINESTERASE INHIBITORS |
| GCN | 18520 |
| HICL Sequence Number | 001990 |
| HICL Sequence Number Description | PYRIDOSTIGMINE BROMIDE |
| Brand/Generic | Generic |
| Proprietary Name | Pyridostigmine Bromide |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | pyridostigmine bromide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SOLUTION |
| Route | ORAL |
| Active Ingredient Strength | 60 |
| Active Ingredient Units | mg/5mL |
| Substance Name | PYRIDOSTIGMINE BROMIDE |
| Labeler Name | Acella Pharmaceuticals, LLC |
| Pharmaceutical Class | Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA212405 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 42192-0626-16 (42192062616)
| NDC Package Code | 42192-626-16 |
|---|---|
| Billing NDC | 42192062616 |
| Package | 473 mL in 1 BOTTLE (42192-626-16) |
| Marketing Start Date | 2023-10-09 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |